Baricitinib 2 mg, 4 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 2 mg, 4 mg

Reference Brands: Olumiant®(EU & US- Emergency Use Authorization (EUA)

Category: Anti Covid Medicines

Baricitinib is an oral JAK inhibitor marketed by Eli Lilly as Olumiant for rheumatoid arthritis, alopecia areata and, depending on the market, atopic dermatitis, juvenile idiopathic arthritis and COVID-19 in hospitalised adults. Baricitinib tablets are made in India under licence for COVID-19; we confirm the manufacturer, licence and patent position, documents and lead time for each order.

Product Description:

Baricitinib blocks the Janus kinase enzymes JAK1 and JAK2, damping the cytokine signalling behind several inflammatory diseases. It was discovered by Incyte and is marketed by Eli Lilly as Olumiant. It is approved in the US and EU for moderate to severe rheumatoid arthritis and severe alopecia areata, in the EU also for atopic dermatitis and juvenile idiopathic arthritis, and in the US for COVID-19 in hospitalised adults who need oxygen or ventilation. Like other JAK inhibitors it carries a boxed warning for serious infections, mortality, cancer, major cardiovascular events and blood clots, which shapes how it is prescribed.

Baricitinib manufacturing in India

In May 2021, during India's second COVID-19 wave, Eli Lilly granted royalty-free voluntary licences to several Indian companies to make and sell baricitinib in India for COVID-19, after the Indian regulator allowed its restricted emergency use with remdesivir. The licences cover COVID-19 use in India only, and baricitinib remains under patent in India and many other countries, so the licence and patent position must be checked for any other use or for export.

Before you buy, check:

• Patent and licence position. Baricitinib is still under patent in many countries, so generic supply depends on the destination and on the terms of any licence.
• Registered indication and strength. Confirm the strengths and indications your registration covers.
• Documents. The site's GMP certificate, a recent Certificate of Analysis and, for registration, bioequivalence data against Olumiant.

We also list baricitinib tablets under arthritis, and other COVID-19 treatments such as remdesivir. Tell us the strength, quantity and market and send us an RFQ.